A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer
Key Points
Advanced lung cancer patients underwent a trial with MSCTRAIL cell therapy alongside standard treatments, aiming for improved outcomes.
The safety profile was assessed, ensuring that combined therapy did not lead to unexpected adverse events in this vulnerable group.
Investigative cell therapy was delivered alongside chemotherapy and immunotherapy, exploring synergistic benefits in treating advanced stages.
Findings highlight potential advancements in lung cancer treatment strategies, implying broader applicability requiring further validation.
Um ensaio clínico de fase I, primeiro em humanos, investigando a segurança e eficácia da terapia celular MSCTRAIL com dosagem repetida, além de quimioterapia e imunoterapia em pacientes com câncer de pulmão avançado. | Synapse